China
/
Pharma
/
SZSE:002262

Jiangsu Nhwa Pharmaceutical Full Year 2024 Earnings: Misses Expectations

Simply Wall St

April 01, 2025

Jiangsu Nhwa Pharmaceutical (SZSE:002262) Full Year 2024 Results

Key Financial Results

Revenue: CN¥5.70b (up 13% from FY 2023).
Net income: CN¥1.14b (up 10% from FY 2023).
Profit margin: 20% (in line with FY 2023).
EPS: CN¥1.13 (up from CN¥1.03 in FY 2023).

002262 Products In Clinical Trials

Phase I: 4.
Phase II: 3.
Phase III: 1.

002262 Post-Clinical Trial Products

Pre-registration: 5.
Approved (during full year): 7.

revenue-and-expenses-breakdown — SZSE:002262 Revenue and Expenses Breakdown April 1st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Jiangsu Nhwa Pharmaceutical Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 1.8%. Earnings per share (EPS) also missed analyst estimates by 5.2%.

The primary driver behind last 12 months revenue was the Manufacturing segment contributing a total revenue of CN¥4.87b (85% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to CN¥1.98b (66% of total expenses). Explore how 002262's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are up 1.7% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Jiangsu Nhwa Pharmaceutical that you should be aware of.

If you're looking to trade Jiangsu Nhwa Pharmaceutical, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.